VolitionRx Limited VNRX

Company Overview

VolitionRx Limited (NYSE American: VNRX), commonly referred to as Volition, is a multi-national epigenetics company focused on developing blood-based, urine-based, and other diagnostic tests designed to detect and monitor cancer and certain other diseases. The company operates primarily within the biotechnology and in vitro diagnostics industries, with its core scientific focus centered on nucleosome measurement and epigenetic biomarkers. Volition’s principal revenue drivers have historically consisted of research collaborations, licensing arrangements, and development-related activities, while the company continues progressing toward broader commercial adoption of its diagnostic platforms.

Volition’s primary technology platform is built around the detection and analysis of circulating nucleosomes, which are fragments of chromatin released into the bloodstream during cellular death processes. The company positions itself as a developer of less invasive diagnostic tools intended to improve early disease detection and patient monitoring. Volition was founded in 2010 and has evolved from an early-stage research organization into a clinical diagnostics company with multiple product candidates and international laboratory operations. Public disclosures and company filings indicate a strategic emphasis on oncology diagnostics, veterinary diagnostics, and applications involving sepsis and inflammatory diseases.